0 Комментарии
0 Поделились
1Кб Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Новости
- ИССЛЕДОВАТЬ
-
Страницы
-
Группы
-
Мероприятия
-
Reels
-
Статьи пользователей
-
Маркет
-
Offers
-
Jobs
-
Войдите, чтобы отмечать, делиться и комментировать!
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Комментарии 0 Поделились 622 Просмотры 0 предпросмотр
-
Rare Disease Genetic Testing Market: Next-Generation Genomic Technologies Reshaping HealthcareThe Rare Disease Genetic Testing Market is witnessing significant transformation, shaped by innovation, evolving consumer expectations, regulatory shifts, and global economic trends. Polaris Market Research’s latest report, Rare Disease Genetic Testing Market, offers a holistic view of the market. It examines the market’s structure, growth drivers, competitive landscape,...0 Комментарии 0 Поделились 2Кб Просмотры 0 предпросмотр